Department of Chemistry and Biochemistry, University of Delaware, Newark, Delaware 19716, United States.
Inorg Chem. 2021 Aug 2;60(15):11154-11163. doi: 10.1021/acs.inorgchem.1c01127. Epub 2021 Jul 15.
Photodynamic therapy (PDT), which involves the photoinduced sensitization of singlet oxygen, is an attractive treatment for certain types of cancer. The development of new photochemotherapeutic agents remains an important area of research. Macrocyclic tetrapyrrole compounds including porphyrins, phthalocyanines, chlorins, and bacteriochlorins have been pursued as sensitizers of singlet oxygen for PDT applications but historically are difficult to prepare/purify and can also suffer from high nonspecific dark toxicity, poor solubility in biological media, and/or slow clearance from biological tissues. In response to these shortcomings, we have developed a series of novel linear tetrapyrrole architectures complexed to late transition metals as potential PDT agents. We find that these dimethylbiladiene () tetrapyrrole complexes can efficiently photosensitize generation of O oxygen upon irradiation with visible light. To extend the absorption profile of the platform, alkynyl-aryl groups have been conjugated to the periphery of the tetrapyrrole using Sonogashira methods. Derivatives of this type containing ancillary phenyl (), naphthyl (), and anthracenyl () groups have been prepared and characterized. In addition to structurally characterizing and , we find that extension of the tetrapyrrole conjugation successfully red-shifts the absorption of the family of biladienes further into the phototherapeutic window (i.e., 600-900 nm). Photochemical sensitization studies demonstrate that our series of new palladium biladiene complexes () can sensitize the formation of O with quantum yields in the range Φ = 0.59-0.73 upon irradiation with light of λ ≥ 650 nm. The improved absorption properties of the complexes in the phototherapeutic window, together with their high O quantum yields, highlight the promise of these compounds as potential agents for PDT.
光动力疗法(PDT)涉及单线态氧的光诱导敏化,是治疗某些类型癌症的一种有吸引力的方法。新的光化学治疗剂的开发仍然是一个重要的研究领域。包括卟啉、酞菁、氯卟啉和细菌叶绿素在内的大环四吡咯化合物已被用作 PDT 应用中单线态氧的敏化剂,但在历史上难以制备/纯化,并且还可能遭受高非特异性暗毒性、在生物介质中的低溶解度和/或从生物组织中的缓慢清除。为了应对这些缺点,我们开发了一系列新型的与后过渡金属配位的线性四吡咯架构,作为潜在的 PDT 试剂。我们发现,这些二甲基双叶啶()四吡咯配合物在可见光照射下可以有效地光敏化 O 的生成。为了扩展 平台的吸收谱,使用 Sonogashira 方法将炔基-芳基基团共轭到四吡咯的外围。已经制备和表征了含有辅助苯基()、萘基()和蒽基()基团的这种类型的衍生物。除了对 和 进行结构表征外,我们发现四吡咯共轭的扩展成功地将双叶啶家族的吸收进一步红移到光疗窗口(即 600-900nm)。光化学敏化研究表明,我们的一系列新钯双叶啶配合物()可以在波长λ≥650nm的光照射下,以量子产率Φ=0.59-0.73敏化 O 的形成。在光疗窗口中, 配合物的吸收特性得到改善,同时具有高 O 的量子产率,这突出了这些化合物作为潜在 PDT 试剂的前景。